BioMarin Pharmaceutical (NASDAQ:BMRN) Given Overweight Rating at Cantor Fitzgerald

BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $86.00 target price on the biotechnology company’s stock. Cantor Fitzgerald‘s price objective points to a potential upside of 54.24% from the stock’s previous close.

BMRN has been the subject of several other research reports. Piper Sandler raised their price target on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Morgan Stanley upped their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Royal Bank Of Canada decreased their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. William Blair upgraded shares of BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Finally, Barclays boosted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $88.60.

BioMarin Pharmaceutical Trading Down 1.2%

Shares of BMRN stock traded down $0.68 during trading hours on Tuesday, reaching $55.76. The company’s stock had a trading volume of 930,236 shares, compared to its average volume of 2,094,454. The stock has a market capitalization of $10.79 billion, a P/E ratio of 150.66, a P/E/G ratio of 0.38 and a beta of 0.22. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The firm’s fifty day simple moving average is $62.46 and its 200 day simple moving average is $58.67. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts expect that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust raised its position in shares of BioMarin Pharmaceutical by 70.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the second quarter worth about $39,000. Keating Financial Advisory Services Inc. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $56,000. Parallel Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 33.9% in the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock worth $100,000 after buying an additional 448 shares in the last quarter. Finally, Plato Investment Management Ltd acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at about $115,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Strong analyst support: Cantor Fitzgerald maintained a Buy-equivalent view on BioMarin, while Raymond James upgraded the stock to Strong Buy with a $109 price target. BioMarin Gets a Buy from Cantor Fitzgerald Raymond James upgrades BioMarin to Strong Buy
• Positive Sentiment: Substantial implied upside: JPMorgan raised its price target from $86 to $87 and reaffirmed an Overweight rating. Cantor Fitzgerald also reiterated its $86 target, indicating analysts see considerable potential appreciation from recent trading levels. Analyst ratings reported by Benzinga
• Positive Sentiment: Favorable broader consensus: BioMarin was included among healthcare stocks carrying Strong Buy ratings and projected double-digit upside, reinforcing the bullish long-term view among some analysts. Healthcare Stocks with Strong Buy Ratings
• Neutral Sentiment: Analyst views are not unanimous: Coverage of BioMarin alongside other healthcare companies highlighted a mixed range of opinions, suggesting potential volatility even though the prevailing recommendations remain favorable. Mixed Analyst Opinions on Healthcare Stocks
• Negative Sentiment: One target was trimmed: Morgan Stanley lowered its price target from $124 to $122, although it retained an Overweight rating. The reduction may weigh on sentiment, but the rating and target still imply significant upside. Morgan Stanley rating reported by Benzinga

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.